Loading...
Please wait, while we are loading the content...
Similar Documents
CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
| Content Provider | MDPI |
|---|---|
| Author | Gagliato, Debora De Melo Buzaid, Antonio C. Perez-Garcia, Jose Manuel Llombart, Antonio Cortes, Javier |
| Copyright Year | 2020 |
| Description | Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly improved progression-free and overall survival. Additionally, other important endpoints, such as the response rate, time to chemotherapy, and a delay in quality of life deterioration, were positively impacted by CDK4/6 inhibitors’ addition to the treatment of advanced HR-positive breast cancer. This review article will summarize current knowledge on CDK4/6 inhibitors in clinical practice for advanced HR-positive metastatic breast cancer, as well as describe recent efforts to more precisely characterize mechanisms of sensitivity and resistance to these drugs, both on the molecular and clinical characterization level. |
| Starting Page | 2480 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers12092480 |
| Journal | Cancers |
| Issue Number | 9 |
| Volume Number | 12 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2020-09-01 |
| Access Restriction | Open |
| Subject Keyword | Cancers Oncology Metastatic Breast Cancer Cdk4/6 Inhibitors Hormone Receptor-positive Breast Cancer |
| Content Type | Text |
| Resource Type | Article |
